LYMA Launches ID² Gut Health System Ahead of June 15 Debut as $240 Billion Supplement Market Faces Doubts
Updated
Updated · Forbes · May 27
LYMA Launches ID² Gut Health System Ahead of June 15 Debut as $240 Billion Supplement Market Faces Doubts
1 articles · Updated · Forbes · May 27
LYMA unveiled ID², a gut-health system built around a “four-dimensional” approach that targets gut coverage, nutrient absorption, cellular integrity and broader resilience; the product is set to launch June 15.
Professor Paul Clayton, LYMA’s science director, argues many supplements fail structurally because consumers use poorly absorbed mineral forms and probiotics without enough prebiotic fibre to help them survive and colonise.
Fibre intake is central to that critique: Clayton says prebiotic consumption has fallen from 40-50 grams a day in the late 19th century to about 4 grams in the average Western diet.
The launch is pitched against a supplement market expected to top $240 billion this year even as gut disease, metabolic dysfunction, fatigue and digestive complaints keep rising, deepening consumer scepticism about wellness products.
LYMA is positioning ID² within a broader luxury-wellness shift from beauty-led optimisation toward “biological infrastructure” such as gut health, recovery and functional ageing, where buyers increasingly demand scientific proof.
With genetics defining supplement success, is this new gut formula already obsolete before its upcoming June 15 launch?
As GLP-1 drugs reshape weight loss, can a gut supplement prove it's a vital partner, not an irrelevant bystander?